Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
iptacopan - CFB inhibitor
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04889430 APPELHUS (CLNP023F12301)
Atypical haemolytic uraemic syndrome
Phase 3
50
Percentage of participants with complete TMA response without the use of PE/PI
and anti-C5 antibody
Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses
of iptacopan
Adult patients with aHUS who are treatment naive to complement inhibitor therapy
(including anti-C5 antibody)
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
References
Abbreviations
Hematology
Biosimilars
Global Health
111 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation